TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04274764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized eHealth Education & Motivational Interviewing
Description: This intervention uses a web-based application to generate personalized education materials for patients based on their eye health screening results and barriers to follow up care. A glaucoma counselor trained in brief, glaucoma-specific motivational interviewing (MI) uses the individualized content generated from this web- based application to form the basis of her conversation with the patient to coach the patient to engage in follow-up care.
Study: NCT00436618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
Study: NCT04170712

Intervention type: OTHER
Intervention: Tampons
Description: Collection of tampons, blood, cervical swabs, tissue and ascites
Study: NCT04292028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The Pilates group participated in an 8-week clinical Pilates training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercises
Description: Control group were given a home-based exercise program.
Study: NCT02595021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total or Subtotal Colectomy
Description: Resect all or most parts of the colon: with total or subtotal colectomy as a part of optimal cytoreductive surgery(residual disease \<=0.5cm)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Other Bowel Resection
Description: Resect part of the colon or small intestine: with other types of bowel resection as a part of optimal cytoreductive surgery(residual disease \<=0.5cm)
Study: NCT01755845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Study: NCT00733304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD
Study: NCT02596620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: Esomeprazole (Nexium)(40 mg) 1 tablet twice daily for 10 days in both arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: Esomeprazole (Nexium)(40 mg) 1 tablet twice daily for 10 days in both arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amolin
Description: Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for the first 5 days in the Sequential arm; Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 10 days for triple therapy arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amolin
Description: Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for the first 5 days in the Sequential arm; Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 10 days for triple therapy arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cravit
Description: Levofloxacin(Cravit)(500 mg) 1 tablet once dialy for the last 5 days in the sequential arm and 1 tablets once daily for 10 days in the triple therapy arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cravit
Description: Levofloxacin(Cravit)(500 mg) 1 tablet once dialy for the last 5 days in the sequential arm and 1 tablets once daily for 10 days in the triple therapy arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flagyl
Description: Metronidazole (Flagyl)(250 mg) 2 # tid for the last 5 days in the sequential arm
Study: NCT02091661

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical retropubic prostatectomy
Description: The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing. Pelvic lymph node dissection is performed if feasible. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiotherapy
Description: External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
Study: NCT00501826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01118325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Drug oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Drug oral treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Drug oral treatment
Study: NCT03532646

Intervention type: PROCEDURE
Group type: OTHER
Intervention: upper endoscopy
Description: endoscopy of the gastrointestinal tract

Intervention type: PROCEDURE
Group type: OTHER
Intervention: upper endoscopy
Description: endoscopy of the gastrointestinal tract
Study: NCT03383549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation
Description: Each subject undergoes a combined rehabilitation protocol, which will be administered on a daily basis, designed to alternate physical exercises and cognitive training. Each daily session lasts between 30 and 45 minutes. The complete protocol lasts 8 weeks.
Study: NCT03421483

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid supplementation
Description: Participants receive a 400 microgram Folic Acid supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Adult Multivitamin
Description: Participants will receive an adult multivitamin supplement
Study: NCT01611753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: packed red blood cell transfusion
Description: Patients wil be randomized en two groups, in the liberal group they must received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL. In the restrictive group they will receive transfusion to maintain hemoglobin levels above 7.0g/dL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: packed red blood cell transfusion
Description: Patients wil be randomized en two groups, in the liberal group they must received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL. In the restrictive group they will receive transfusion to maintain hemoglobin levels above 7.0g/dL
Study: NCT03421483

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Adult Multivitamin
Description: Participants will receive an adult multivitamin supplement
Study: NCT00738933

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary plant stanols
Description: Daily 2 grams of plant stanols in a margarine preparation for 4-8 weeks before the operation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary plant sterols
Description: Daily 2 grams of plant sterols in a margarine preparation for 4-8 weeks before the operation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Margarine product without plant stanol or sterol esters
Study: NCT04279717

Intervention type: OTHER
Intervention: Observation
Description: No interventions planned: treatment of patients at the discretion of the treating/responsible physician

Intervention type: OTHER
Intervention: Observation
Description: No interventions planned: treatment of patients at the discretion of the treating/responsible physician
Study: NCT02766023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus CTV-05
Description: LACTIN-V is an intravaginal live biotherapeutic product composed of Lactobacillus crispatus CTV-05 (LACTIN-V, Osel Inc) in a vaginal applicator. Subjects receive 2x10\^9 cfu/dose applied vaginally daily x 5 days then twice weekly x 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days
Study: NCT00528567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard adjuvant chemotherapy
Description: All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard adjuvant chemotherapy
Description: All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
Study: NCT01410435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monofer
Description: Infusion according to current HB level
Study: NCT03455192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synbiotic Supplement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT01839162

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Description: Diagnostic coronary angiography

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Coronary angiography
Description: Diagnostic coronary angiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Description: Diagnostic coronary angiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Description: Diagnostic coronary angiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: PCI
Description: Percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right approach
Description: Right transradial access

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Right approach
Description: Right transradial access

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right approach
Description: Right transradial access

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right approach
Description: Right transradial access

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left approach
Description: Left transradial access

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Left approach
Description: Left transradial access

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left approach
Description: Left transradial access

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left approach
Description: Left transradial access
Study: NCT01132066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will lead to an increase in cortical excitability

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Sham will provide identical subjective sensation as tDCS
Study: NCT01513525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits
Study: NCT01012154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomicroscope
Description: Endomicroscopic images and biopsies are taken at several positions on the tumor.
Study: NCT03601936

Intervention type: DEVICE
Group type: OTHER
Intervention: Evivo Infant Gut Bifidobacterium Screening Test
Description: Operators at each test site will collect and test infant stool specimens according to the Evivo Infant Gut Bifidobacterium Screening Test protocol.
Study: NCT01803477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: once daily for two consecutive days (Picato)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: once daily for two consecutive days (Picato)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: once daily for two consecutive days (Picato)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: once daily for two consecutive days (Picato)
Study: NCT00695851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCK3145
Description: i.v. bolus either 15 mg/m2 weekly of PCK3145.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCK3145
Description: by i.v. bolus 7.5 mg/m2 twice per week of PCK3145
Study: NCT00665743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400
Description: naproxen 500 mg /esomeprazole 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: naproxen 500 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: naproxen 500 mg
Study: NCT03422289

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: myo-inositol plus folic acid
Description: this treatment is made in the first phase of the study for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: myo-inositol plus folic acid plus alpha-lactalbumin
Description: this treatment is made in the second phase of the study and it has a new molecule added to the previous ones administered in the first phase of the study
Study: NCT00490633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ear Loop Procedure Mask
Description: Facemasks were requested to be worn while participants were in the residence hall for year one, and while they were in residence halls for a minimum of six hours per day in year two.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ear Loop Procedure Mask
Description: Facemasks were requested to be worn while participants were in the residence hall for year one, and while they were in residence halls for a minimum of six hours per day in year two.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 62% Ethyl Alcohol Hand Sanitizer
Description: Hand sanitizer was provided to participants in the facemask and hand hygiene arm for year one and year two of the study.
Study: NCT04281589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: if the ventilation parameter caused desaturation or hypercapnia we will change the parameter
Description: we will increased fi02

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: if the ventilation parameter caused desaturation or hypercapnia we will change the parameter
Description: we will increased fi02

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: if the ventilation parameter caused desaturation or hypercapnia we will change the parameter
Description: we will increased fi02

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: if the ventilation parameter caused desaturation or hypercapnia we will change the parameter
Description: we will increased fi02
Study: NCT02556866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00201838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
Study: NCT03654014

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SofPulse
Description: SofPulse PEMF device treatment of the brain after traumatic injury

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SofPulse
Description: SofPulse PEMF device treatment of the brain after traumatic injury

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SofPulse
Description: SofPulse PEMF device treatment of the brain after traumatic injury
Study: NCT02172287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (Ba679 BR)
Description: One capsule once daily by oral inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Inhalation aerosol twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Tiotropium )
Description: Placebo for Tiotropium delivered by inhalation capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Tiotropium )
Description: Placebo for Tiotropium delivered by inhalation capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Salmeterol)
Description: Placebo for Salmeterol delivered by inhalation aerosol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Salmeterol)
Description: Placebo for Salmeterol delivered by inhalation aerosol
Study: NCT03519685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive Training and Education
Description: Staff at the student health center and local health centers where they refer for contraceptive services will receive a CME-accredited education and training session and technical assistance. The one-day session emphasizes evidence-based and patient-centered contraceptive counseling and provision. Students attending colleges assigned to the intervention arm will receive materials and resources designed to educate young people about contraceptive methods and where to access services.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nutrition Education
Description: Students attending colleges assigned to the nutrition education arm will receive materials and resources designed to educate young people about the impacts of sugar on health.
Study: NCT02613689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduled Gradual Reduction (SGR)
Description: Participants in this group will group will receive the Scheduled Gradual Reduction (SGR) smokeless tobacco cessation reduction intervention via text message over a period of four weeks. Participants will initially report their smokeless tobacco use according to their usual habit, and over the course of the intervention be directed via text message precise times to start and stop each instance of smokeless tobacco use, gradually reducing the occurrences of use. In addition, this group will also receive the support messages that are sent to the control group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messages
Description: Participants in this group will receive text messages about smokeless tobacco cessation in the form of counseling messages at various times throughout the day over a period of four weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages
Description: Participants in this group will receive text messages about smokeless tobacco cessation in the form of counseling messages at various times throughout the day over a period of four weeks.